13F filer · CIK 942257
INTERNATIONAL BIOTECHNOLOGY TRUST PLC
London, X0 · filing since Q4 2016 · last filing Nov 14, 2023
Reported value
$296.8M
$-31.7M vs prior
Positions
65
New / sold out
9 / 5
Added / reduced
18 / 13
Turnover
24.3%
buys $76.1M · sells $91.5M
Top-10 weight
47.8%
Biggest buys vs Q2 2023
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | BIOMARIN PHARMACEUTICAL I | +95,000 | +162.0% | +$8.4M |
| Added | UNIQURE N.V. COM EUR0.05 | +1,226,000 | +7909.7% | +$8.2M |
| Added | BIOGEN INC COMMON STOCK | +29,200 | +265.5% | +$7.5M |
| Added | INTRA-CELLULAR THERAPIES | +141,000 | +79.7% | +$7.3M |
| Added | GILEAD SCIENCES INC COMMO | +89,000 | +61.6% | +$6.7M |
| Added | ULTRAGENYX PHARMACEUTICAL | +170,000 | +212.4% | +$6.1M |
| Added | AMYLYX PHARMS. | +270,000 | +1080.0% | +$4.9M |
| Added | AURINIA PHARMACEUTICALS I | +467,000 | +81.4% | +$3.6M |
| New | ASTRAZENECA PLC SPONSORED | +46,500 | – | +$3.1M |
| New | CRISPR THERAPEUTICS AG CO | +63,000 | – | +$2.9M |
17 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q2 2023
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | REGENERON PHARMACEUTICALS | -18,153 | -67.2% | $-14.9M |
| Sold out | APELLIS PHARMS. | -129,700 | -100.0% | $-11.8M |
| Reduced | AMGEN INC COM | -38,000 | -32.4% | $-10.2M |
| Reduced | Harmony Biosciences Holdi | -256,000 | -44.9% | $-8.4M |
| Reduced | ALNYLAM PHARMACEUTICALS I | -44,800 | -54.9% | $-7.9M |
| Sold out | HORIZON THERAPEUTICS | -67,000 | -100.0% | $-6.9M |
| Sold out | TRAVERE THERAPEUTICS INC | -441,019 | -100.0% | $-6.8M |
| Reduced | NEUROCRINE BIOSCIENCES IN | -40,000 | -58.1% | $-4.5M |
| Reduced | UNITED THERAPEUTICS CORP | -18,800 | -35.6% | $-4.2M |
| Reduced | AKERO THERAPEUTICS INC CO | -60,000 | -76.4% | $-3.0M |
8 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q3 2023
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | AMGEN INC COMCOM | 79,246 | $21.3M | 7.17% |
| 2 | INCYTE CORP INC COMCOM | 358,454 | $20.7M | 6.97% |
| 3 | GILEAD SCIENCES INC COMMOCOM | 233,584 | $17.5M | 5.90% |
| 4 | INTRA-CELLULAR THERAPIESCOM | 317,856 | $16.5M | 5.57% |
| 5 | BIOMARIN PHARMACEUTICAL ICOM | 153,656 | $13.6M | 4.58% |
| 6 | SUPERNUS PHARMACEUTICALSCOM | 426,500 | $11.8M | 3.96% |
| 7 | VERA THERAPEUTICSCL A | 758,355 | $10.4M | 3.50% |
| 8 | BIOGEN INC COMMON STOCKCOM | 40,200 | $10.3M | 3.48% |
| 9 | Harmony Biosciences HoldiCOM | 314,500 | $10.3M | 3.47% |
| 10 | MIRATI THERAPEUTICS INC CCOM | 216,000 | $9.4M | 3.17% |
55 more rows. Subscribe for $29/month to see every row, download the data and use the API.